Effect of MIC interpretative breakpoint revision on cephalosporin and carbapenem susceptibility among ESBL-producing Enterobacteriaceae

1. Kiratisin P, Chattammanat S, Sa-Nguansai S, Dansubutra B, Nangpatharapornthawee P, Patthamalai P, et al. A 2 year trend of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Thailand: an alert for infection control. Trans R Soc Trop Med Hyg. 2008; 102:460-4.10.1016/j.trstmh.2008.02.005Open DOISearch in Google Scholar

2. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Pensylvania: CLSI; 2009.Search in Google Scholar

3. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009; 9:228-36.10.1016/S1473-3099(09)70054-4Open DOISearch in Google Scholar

4. Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2006; 26:129-34.10.1592/phco.2006.26.1.12916506354Open DOISearch in Google Scholar

5. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokineticspharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis. 2007; 44:79-86.10.1086/51007917143821Open DOISearch in Google Scholar

6. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009; 22:161-82.10.1128/CMR.00036-08262063719136439Open DOISearch in Google Scholar

7. Robberts FJ, Kohner PC, Patel R. Unreliable extendedspectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates. J Clin Microbiol. 2009; 47:358-61.10.1128/JCM.01687-08264368219109470Open DOISearch in Google Scholar

8. Kiratisin P, Henprasert A. Resistance phenotypegenotype correlation and molecular epidemiology of Citrobacter, Enterobacter, Proteus, Providencia, Salmonella and Serratia that carry extended-spectrum -lactamases with or without plasmid-mediated AmpC _-lactamase genes in Thailand. Trans R Soc Trop Med Hyg. 2011; 105:46-51.10.1016/j.trstmh.2010.07.01020880563Open DOISearch in Google Scholar

9. Jones RN, Craig WA, Ambrose PG, Dudley MN, Pottumarthy S. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing ESBLs. Diagn Microbiol Infect Dis. 2005; 52:235-46.10.1016/j.diagmicrobio.2005.02.00616105568Open DOISearch in Google Scholar

10. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 2006; 54:231-6.10.1016/j.diagmicrobio.2005.09.01116423491Open DOISearch in Google Scholar

11. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006; 119 Suppl 1:S20-S8.10.1016/j.amjmed.2006.03.01316735147Open DOISearch in Google Scholar

12. Frei CR, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother. 2008; 61:621-8.10.1093/jac/dkm536295274018252694Search in Google Scholar

13. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae: EUCAST and CLSI breakpoints. Clin Microbiol Infect. 2008; 14 Suppl 1:169-74.10.1111/j.1469-0691.2007.01856.x18154542Open DOISearch in Google Scholar

14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Pensylvania: CLSI; 2010.Search in Google Scholar

15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement (June 2010 Update). Document M100-S20-U. Pensylvania: CLSI; 2010.Search in Google Scholar

16. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-â-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother. 2008; 52:2818-24.10.1128/AAC.00171-08249313618505851Search in Google Scholar

17. Kiratisin P, Henprasert A. Genotypic analysis of plasmid-mediated beta-lactamases amongst Enterobacteriaceae other than Escherichia spp. And Klebsiella spp. that are non-susceptible to a broadspectrum cephalosporin. Int J Antimicrob Agents. 2010; 36:343-7.10.1016/j.ijantimicag.2010.06.02920688485Open DOISearch in Google Scholar

18. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect. 2005; 11 Suppl 6:10-7.10.1111/j.1469-0691.2005.01265.x16209701Open DOISearch in Google Scholar

19. Ramphal R, Ambrose PG. Extended-spectrum betalactamases and clinical outcomes: current data. Clin Infect Dis. 2006; 42 Suppl 4:S164-S72.10.1086/50066316544267Open DOISearch in Google Scholar

20. Wong-Beringer A, Hindler J, Loeloff M, Queenan AM, Lee N, Pegues DA, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis. 2002; 34:135-46.10.1086/32474211740699Open DOISearch in Google Scholar

21. Paterson DL, Bonomo RA. Extended-spectrum â-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18:657-86.10.1128/CMR.18.4.657-686.2005126590816223952Open DOISearch in Google Scholar

22. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010; 300:371-9. 10.1016/j.ijmm.2010.04.00520537585Open DOISearch in Google Scholar